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TGFβ pathway limits dedifferentiation following WNT
and MAPK pathway activation to suppress intestinal
tumourigenesis
Patrizia Cammareri1, David F Vincent1, Michael C Hodder1, Rachel A Ridgway1, Claudio Murgia1, Max Nobis1, Andrew D Campbell1,
Julia Varga2, David J Huels1, Chithra Subramani1, Katie LH Prescott1, Colin Nixon1, Ann Hedley1, Simon T Barry3, Florian R Greten2,4,
Gareth J Inman5 and Owen J Sansom*,1,6
Recent studies have suggested increased plasticity of differentiated cells within the intestine to act both as intestinal stem cells
(ISCs) and tumour-initiating cells. However, little is known of the processes that regulate this plasticity. Our previous work has
shown that activating mutations of Kras or the NF-κB pathway can drive dedifferentiation of intestinal cells lacking Apc. To
investigate this process further, we profiled both cells undergoing dedifferentiation in vitro and tumours generated from these cells
in vivo by gene expression analysis. Remarkably, no clear differences were observed in the tumours; however, during
dedifferentiation in vitro we found a marked upregulation of TGFβ signalling, a pathway commonly mutated in colorectal cancer
(CRC). Genetic inactivation of TGFβ type 1 receptor (Tgfbr1/Alk5) enhanced the ability of KrasG12D/+ mutation to drive
dedifferentiation and markedly accelerated tumourigenesis. Mechanistically this is associated with a marked activation of MAPK
signalling. Tumourigenesis from differentiated compartments is potently inhibited by MEK inhibition. Taken together, we show that
tumours arising in differentiated compartments will be exposed to different suppressive signals, for example, TGFβ and blockade
of these makes tumourigenesis more efficient from this compartment.
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Since the description of ‘top-down’ adenoma formation of
colorectal tumours there has been discussion over the cell of
origin of colorectal cancer (CRC). Here, human dysplastic
crypts, carrying mutations of the APC tumour suppressor
gene, were detectable exclusively at the top part of colonic
crypts in patients with adenomatous polyps.1 Importantly, cells
at the base of the crypts, on which the polyps were located,
were morphologically normal and did not carry an
APCmutation. However, histopathological analyses have also
suggested a stem cell route through to the identification of
monocryptal adenomas in patients who develop familial
adenomatous polyposis due to a germline mutation in
APC, supporting the ‘bottom-up’ model of intestinal
tumourigenesis.2
To elucidate the cell of origin of human CRC, many studies
have used ‘proof-of-concept’ approaches using genetically
engineered mice to target different cell types and assess if
they initiate tumourigenesis. This extensive work has also
suggested two routes of intestinal cancer. In support of the
‘bottom-up’ model, one efficient route is where intestinal stem
cells (ISCs) are transformed via Apc loss or stable expression
of β-catenin and very rapidly form adenomas.3–5 At the same
time, experimental evidence also supports the ‘top-down’
model of intestinal tumourigenesis, where non-ISCs are
transformed and serve as cells of origin. However, non-ISCs
alongside Apc loss require additional events to initiate
tumourigenesis.6–8 Activation of oncogenic KrasG12D/+ or
NF-κB activation concomitantly with Apc loss can drive a
dedifferentiation programme within the villus epithelium.6 It
has also been shown that the long-lived differentiated
DCLK1+ve Tuft cells can act as a cell of origin for intestinal
cancer8 if Apc loss was combined with inflammation. More-
over, elegant work by Davis et al.9 showed that the stromal
microenvironment has a critical role in suppressing dediffer-
entiation. Disruption of the Gremlin-1 morphogen gradient
within the intestinal epithelium led to the formation of ‘crypts in
villus’, indicating that Apc-deficient enterocytes indeed
dedifferentiated.
Recent sequencing studies have confirmed that in CRC
alongside APC mutation there are common mutations in
KRAS, TP53 andPI3KCA genes. Additionally, the TGFβ family
members are also very commonly mutated or deregulated.10
Deletion, downregulation or inactivating mutations can occur
inTGFBR1,TGFBR2and theSMADeffectors (SMAD2–4).11–13
Frameshift mutations in TGFBR2 have been predominantly
identified in CRC with mismatch repair (MMR) defects.14 In
tumours with functional MMR, TGFβ signalling is commonly
abolished by loss of SMAD4.11,15
In addition to this clear tumour-suppressive role, TGFβ
signalling also has tumour-promoting effects in the late stages
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of CRC. Enhanced levels of TGFβ ligand expression has been
associated with advanced tumours,16 and the activation of an
epithelial-to-mesenchymal transition (EMT) programme.17,18
High levels of TGFβ target genes, in the stromal cells of CRC
patients, are associated with poor prognosis,19 and in the
recent publication of the consensus molecular subtypes of
human CRC, high levels of TGFβ signalling define a
mesenchymal subtype with the poorest prognosis.20
Since TGFβ signalling is commonly deregulated in CRC, we
functionally explored the importance of this pathway and found
that the likely driving force, behind these mutations, is the
inhibition of its prodifferentiation tumour-suppressive effect.
Mechanistically further deregulation of MAPK signalling is
important for this phenotype.
Results
Transcriptome profiling of tumours derived from crypts
versus villi failed to reveal major differences. Acute
deletion of Apc in the intestinal epithelium, using VillinCreER
(referred to from now on as VilCreERApcfl/fl), causes a crypt-
progenitor phenotype characterized by enlarged intestinal
crypts when compared with the wild-type intestine
(Figure 1a). An additional oncogenic mutation in Kras
(referred to from now on as VilCreERApcfl/flKrasG12D/+) results
in a marked increase in crypt size (Figure 1a) with the
presence of proliferative cells in the villus, which are not
detected in wild-type or VilCreERApcfl/fl mice (Figures 1b
and c), showing that the additional mutation of Kras can drive
proliferation in differentiated enterocytes.
In our previous studies, we have demonstrated that villi
purified from VilCreERApcfl/flKrasG12D/+ mice grow in vitro as
spheroids with tumourigenic capacity (unlike villi purified from
either wild-type or VilCreERApcfl/fl mice).6 To investigate this
process further, we analysed the transcriptomes of tumours
derived through subcutaneous injection of either spheroids
derived from crypts (CDS) or Villi (VDS) purified from
VilCreERApcfl/flKrasG12D/+ mice. Surprisingly, our microarray
analysis revealed no consistent differences between tumours
derived from injection of CDS or VDS (Supplementary Data 1),
indicating that in these models the cell of origin did not modify
the transcriptional profile of the tumours. This also suggested
that dedifferentiation, provoked by WNT activation and
KrasG12D/+ mutation, was complete and that, after transplan-
tation, the cell of origin does not affect subsequent gene
expression. To investigate this in an autochthonous environ-
ment, we then compared gene expression when WNT
pathway activation (using a β-catenin mutant that cannot be
targeted for degradation – referred to as CtnnbloxEx3/+),
coupled with an oncogenic KrasG12D/+mutation, was targeted
to just differentiated cells, using Xbp1sCreER, or to all cells,
using VilCreER. Remarkably, expression profiles from epithe-
lial extractions (performed when intestines showed a similar
crypt-progenitor phenotype, 7 days for VilCreER and 21 days
for Xbp1sCreER) did not reveal any significant differences,
again suggesting that once cells had undergone dedifferentia-
tion the gene expression pattern of the initiating cells is lost
(Supplementary Data 2a and b).
TGFβ signalling pathway is upregulated following WNT
and oncogenic KRAS activation. We reasoned that to
have a better understanding of the pathways responsible for
dedifferentiation, we would need to investigate transcriptional
changes as the process was occurring. For this reason, we
profiled VDS versus CDS, purified from VilCreERApcfl/fl
KrasG12D/+ mice, while they were still in culture. This
approach proved more successful, and we were able to
observe significant deregulation of a number of different
growth signalling pathways (fold-change cutoffs⩾ 1.5,
P⩽ 0.05; Supplementary Figure 1a and Supplementary
Data 3). It was particularly notable that numerous members
of the TGFβ family and superfamily were upregulated in the
VDS compared with CDS (fold-change cutoffs⩾ 1.5;
Supplementary Table 1 and Supplementary Data 3). To
assess whether upregulation of TGFβ signalling was also
occurring in vivo, we examined the activity of TGFβ signalling
immediately after combined acute loss of Apc and KrasG12D/+
mutation. We detected phosphorylated SMAD3 (pSMAD3)
positivity mainly in the villus aberrant foci when compared
with the adjacent normal epithelium in VilCreERApcfl/fl
KrasG12D/+ mice (Figure 1d and Supplementary Figure 1b).
Furthermore, p21 (a mediator of TGFβ signalling) was highly
expressed in the VilCreERApcfl/flKrasG12D/+ villi when com-
pared with wild-type villi (Figure 1e). We also observed
increased levels of Smad7 (a canonical TGFβ target gene) in
VilCreERApcfl/flKrasG12D/+ mice along the crypt–villus axis
compared with wild-type intestine (Supplementary Figure 1c).
We then assessed the activation state of the TGFβ signalling
pathway in intestinal tumours developed in VilCreERApcfl/+
KrasG12D/+mice. Thesemice develop tumours in both the small
and large intestine upon loss of the remaining wild-type Apc
allele (Supplementary Figure 2a). Importantly, tumours from
these mice resemble both the top-down (Supplementary
Figures 2b and d) and bottom-up morphologies (Supplem-
entary Figures 2c and d). Importantly, we detected high levels of
pSMAD3 and p21 in the top-down lesions, indicating an
activation of TGFβ signalling (Supplementary Figures 2e
and f). Tumours generated according to the bottom-up model
show a morphogenic pSMAD3 gradient along the crypt–villus
axis (Supplementary Figure 2g).
Thus, these results suggest that WNTand KRAS signalling
can promote TGFβ signalling, particularly in cells that are
dedifferentiating at crypt–villus junctions.
TGFβ signalling in wild-type intestine is higher as cells
differentiate but is not essential for homeostasis. The
TGFβ pathway has been previously reported to form a
gradient along the vertical axis of the intestinal epithelium
with the highest activity in differentiated cells and lowest
activity in the crypt.21 However, studies that have genetically
ablated TGFβ signalling either via receptor or SMAD4
deletion, have not reported marked effects on
homeostasis.22,23 For our studies if tumour cells arise further
up the crypt–villus axis, they may be exposed to a high level
of TGFβ signalling that might prevent dedifferentiation and
limit proliferation. We first examined the expression of TGFβ
signalling components in wild-type intestine. We compared
Tgfbr1 and Tgfbr2mRNA expression in freshly purified crypts
with villi (which include intravillus stromal cells). mRNA of
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both receptors was detectable in both compartments with
higher levels in the villus (Figures 2a and b). The Tgfb1 ligand
expression was mainly detected in the intravillus region
(Figure 2c), suggesting that the differentiated compartment
might be exposed to more ligand and therefore activate TGFβ
signalling to a higher extent. We then stained wild-type
Figure 1 KrasG12D/+ enhances both the crypt-progenitor phenotype and transforming growth factor-β (TGFβ) pathway activation following Apc loss. (a) Haematoxylin and
eosin (H&E) staining and a schematic model of the crypt-progenitor phenotype of wild-type (WT), VilCreERApcfl/fl (Vil Apcfl/fl) and VilCreERApcfl/flKrasG12D/+ (Vil Apcfl/flKrasG12D/+)
small intestine. Note the presence of dedifferentiated cells (black arrow) in the villus of the Vil Apcfl/flKrasG12D/+genotype. Black bars highlight the differences in crypt length. (b)
Bromodeoxyuridine (BrdU) staining of WT, Vil Apcfl/f and Vil Apcfl/flKrasG12D/+ small intestine. Note the presence of proliferating cells (black arrow) in the villi of the Vil Apcfl/
flKrasG12D/+genotype. (c) Quantification of total BrdU+ cells demonstrating increased proliferation in the Vil Apcfl/flKrasG12D/+ genotype. Error bars represent mean± S.E.M.,
*P= 0.04 Mann–Whitney test, one-tailed, n= 3 biological replicates. (d) pSMAD3 and (e) p21 IHC analysis of intestine from WT and Vil Apcfl/flKrasG12D/+ mice. Black arrows
indicate positive cells in the villi. High magnification insets highlight the presence of positive cells. Scale bars, 100 μm
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intestines for pSMAD3. Nuclear pSMAD3 was mainly
detected in the late transit-amplifying and differentiated cells
(Figure 2d).
In line with previous studies, deletion of either Tgfbr1
(VilCreERTgfbr1fl/fl) or the key downstream transcription factor
SMAD4 (VilCreERSmad4fl/fl) had no impact on intestinal
proliferation. Normal levels of proliferation were observed
4 days after conditional deletion when compared with wild-
type intestine (Figures 2e and f). Taken together, these data
indicate that canonical TGFβ signalling is higher in the
Figure 2 Loss of transforming growth factor-β (TGFβ) signalling does not affect the normal homeostatic proliferation. (a) Quantitative real-time-PCR (qRT-PCR) analysis of
Tgfbr1 and (b) Tgfbr2 expression in wild-type freshly purified crypts (WT-Crypt) versus villi (WT-Villus). Data are shown as ratios to the internal Gapdh control with error bars
representing mean±S.E.M., *P= 0.04 by Mann–Whitney test, one-tailed, n= 3 biological replicates. (c) RNAscope analysis of Tgfb1 inWT crypt and villus. Scale bars, 20 μm.
(d) IHC analysis of pSMAD3 on WT small intestine. (e) Haematoxylin and eosin (H&E) and bromodeoxyuridine (BrdU) staining of WT, VilCreERTgfbr1fl/fl (Vil Tgfbr1fl/fl) and
VilCreERSmad4fl/fl (Vil Smad4fl/fl) small intestine 4 days post induction with tamoxifen. Scale bars, 100 μm. (f) Quantification of total BrdU+ cells in WT, Vil Tgfbr1fl/fl and
Vil Smad4fl/fl small intestine. Error bars represent mean± S.E.M., n= 3 biological replicates
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differentiated compartment of the intestine and could have a
role in suppressing dedifferentiation even in the absence of a
homeostatic role.
Loss of TGFβ signalling is not sufficient to drive
dedifferentiation if only Apc is deleted. Analysis of our
previous microarray,24 comparing the transcriptomes of wild-
type intestine to intestine where Apc has been acutely
deleted, showed that Tgfbr1 is upregulated following acute
Apc loss. To confirm this, we analysed the expression of
TGFβ signalling components in VilCreERApcfl/fl mice 4 days
post induction and compared this with wild-type mice. We
observed a marked increase in Tgfbr1 mRNA levels in the
crypts but not the villi (Figures 3a and b and Supplementary
Figure 3a).
Similar to the wild-type intestine, stromal cells were themain
source of TGFβ1 (Supplementary Figure 3b). After Apc
deletion, Smad7 mRNA was detectable in both crypts and
villi (Supplementary Figure 3c) and p21 was strongly induced
at the crypt–villus transition zone (Supplementary Figure 3d).
To test the functional importance of TGFβ signalling
upregulation following Apc loss, we generated VilCreERApcfl/fl
Tgfbr1fl/fl mice and analysed the crypt-progenitor phenotype
4 days post induction. Surprisingly, crypt size and the number
of proliferative cells were not increased by Tgfbr1 loss
(Figures 3c–e), suggesting that in the absence of Kras
mutation, Tgfbr1 deficiency was insufficient to drive dediffer-
entiation. Accordingly, villi purified from VilCreERApcfl/fl
Tgfbr1fl/fl mice were unable to form spheroids in vitro
(Supplementary Figure 3e). Interestingly, Tgfbr1 loss
increased the mRNA expression levels of the stem cells
markers Lgr5 and Olfm4 in CDS (Figures 3f and g). To
functionally test this, we then generated single-cell clones and
observed that Tgfbr1 loss increased the number of cells with
clonogenic potential. (Supplementary Figure 3f). These data
are consistent with work by Batlle and co-workers25 who
suggested that loss of TGFβ signalling increases stem cell
properties and that TGFBR1/ALK5 inhibitors are required for
human colonic organoid cultures.
We then aged VilCreERApcfl/+Tgfbr1fl/fl mice until they
developed clinical signs. We observed a significant decrease
in tumour latency compared with VilCreERApcfl/+ mice
(Supplementary Figure 3g). However, in contrast to VilCreER-
Apcfl/+KrasG12D/+ mice, there was no presence of top-down
lesions. Consistent with previous studies,22,26 the major
consequence of Tgfbr1 loss on tumourigenesis was the
development of invasive adenocarcinomas with E-cadherin+ve
cells at the invasive front (Supplementary Figures 3h and i).
Overall, these data show that while loss of TGFβ can drive
progression of adenomas to adenocarcinoma, it is not
sufficient to drive dedifferentiation in the absence of the
KrasG12D mutation.
Loss of TGFβ signalling increases the crypt-progenitor
phenotype and accelerates tumourigenesis when both
Apc and Kras are mutated. Given that Kras mutation
appears to be critical for dedifferentiation and that we
observed increased TGFβ signalling in VDS compared with
CDS, we generated the VilCreERApcfl/flKrasG12D/+Tgfbr1fl/fl
mouse model to assess if this modified the acute crypt-
progenitor phenotype of VilCreERApcfl/flKrasG12D/+ mice.
Tgfbr1 loss now significantly increased the crypt-progenitor
phenotype of VilCreERApcfl/flKrasG12D/+ mice (Figure 4a).
Importantly, proliferative cells were observed even further into
the top part of the villus, suggesting enhanced proliferation
(Figures 4b and c). Loss of TGFβ signalling was again
associated with an increased expression of Lgr5 and Olfm4 in
CDS (Supplementary Figures 4a and b) and with an
increased clonogenic potential (Supplementary Figure 4c).
We also observed increased Lgr5 and Olfm4 expression
levels in the crypts of VilCreERApcfl/flKrasG12D/+Tgfbr1fl/fl mice
when compared with VilCreERApcfl/flKrasG12D/+ mice.
Whereas Lgr5 and Olfm4 levels in the villi were negligible
at an early time point (Supplementary Figures 4d and e). To
assess whether the increased crypt-progenitor phenotype
observed in VilCreERApcfl/flKrasG12D/+Tgfbr1fl/fl mice trans-
lated into enhanced tumourigenesis, we generated cohorts of
VilCreERApcfl/+KrasG12D/+ and VilCreERApcfl/+KrasG12D/+
Tgfbr1fl/fl mice and aged them until they showed clinical
signs. Tgfbr1 deletion accelerated intestinal tumourigenesis
(Figure 4d). VilCreERApcfl/+KrasG12D/+Tgfbr1fl/fl mice devel-
oped tumours both in the small intestine and colon.
Importantly, many lesions were now observed with histologi-
cal characteristics reminiscent of top-down lesions, suggest-
ing that they had arisen from differentiated compartments
(Figures 4e and f), and 50% of mice developed in situ
invasive tumours (Supplementary Figure 4f). Overall, these
data suggest that TGFβ signalling acts as a potent tumour
suppressor in the presence of WNT and RAS pathway
activation, limiting proliferation, stem cell marker expression
and potentially plasticity/dedifferentiation.
Loss of TGFβ signalling promotes dedifferentiation. To
study the role of TGFβ on dedifferentiation in more detail, we
took advantage of the villus culture system. We purified villi
from VilCreERApcfl/flKrasG12D/+ and VilCreERApcfl/flKrasG12D/+
Tgfbr1fl/fl mice and monitored the formation of organoids
in vitro. Tgfbr1 loss increased the efficacy of spheroid
formation from villi (Figures 5a and b), confirming the role
of TGFβ in restraining dedifferentiation. VilCreERApcfl/fl
KrasG12D/+Tgfbr1fl/fl VDS can be propagated long term in
culture and have tumourigenic potential. Allograft tumours
showed strong expression of the stem cell markers Lgr5 and
CD44v6 (Supplementary Figures 5a–c).
To test whether increasing TGFβ would further suppress
dedifferentiation, we treated VilCreERApcfl/flKrasG12D/+ villi
with TGFβ1 and found that exogenous TGFβ1 reduced the
capacity to form spheroids in vitro (Figure 5c). Taken together,
these data confirmed that loss of TGFβ signalling increases
dedifferentiation.
Loss of TGFβ pathway increases pERK levels and
induces sensitivity to a MEK1/2 inhibition. We next
examined the mechanism by which Tgfbr1 loss caused
increased dedifferentiation and accelerated tumourigenesis.
Previous studies have shown crosstalk between the MAPK
and TGFβ pathways.27,28 pERK immunohistochemistry (IHC)
showed a striking upregulation in the VilCreERApcfl/fl
KrasG12D/+Tgfbr1fl/fl mice compared with the VilCreERApcfl/fl
KrasG12D/+ mice (Figure 6a). To measure precisely ERK
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activation, VilCreERApcfl/fl, VilCreERApcfl/flKrasG12D/+ and
VilCreERApcfl/flKrasG12D/+Tgfbr1fl/fl CDS were transfected
with an ERK-FRET activity biosensor (we used the EKAREV
biosensor consisting of an msECFP donor and YPet
acceptor29) and treated with EGF for 45 min. A decreased
lifetime indicates an activation of the nuclear biosensor. As
expected, the fluorescence lifetime decreased following EGF
administration in all three genotypes. Importantly, the activa-
tion of ERK was higher in the absence of Tgfbr1 (Figure 6b).
To test functionally whether MAPK pathway activation was
required for faster tumourigenesis, we treated VilCreERApcfl/+
KrasG12D/+Tgfbr1fl/fl mice with the potent allosteric MEK1/2
inhibitor Selumetinib (AZD-6244, ARRY-142886). Treatment
started 1 day post induction and was able to reverse the
acceleration of tumourigenesis conferred by Tgfbr1 loss so
that VilCreERApcfl/+KrasG12D/+Tgfbr1fl/fl mice now had a
median survival similar to vehicle-treated VilCreERApcfl/+
KrasG12D/+ (Figure 6c). Interestingly, this effect was not
Figure 3 Tgfbr1 is upregulated following Apc loss. (a) RNAscope of Tgfbr1 on wild-type (WT) and VilCreERApcfl/fl (Vil Apcfl/fl) crypts. Note the increased positivity following
Apc loss. Scale bars, 20 μm. (b) Quantitative real-time-PCR (qRT-PCR) analysis of Tgfbr1 onWT and Vil Apcfl/fl crypts. Data are shown as ratios to the internalGapdh control with
error bars representing mean± S.E.M., *P= 0.04 by Mann–Whitney test, one-tailed, n= 3 biological replicates. (c) Haematoxylin and eosin (H&E) and (d) bromodeoxyuridine
(BrdU) staining on Vil Apcfl/fl and VilCreERApcfl/flTgfbr1fl/fl (Vil Apcfl/flTgfbr1fl/fl) intestine 4 days post induction with tamoxifen. Scale bars, 100 μm. (e) Quantification of total BrdU+
cells of Vil Apcfl/fl and Vil Apcfl/fl Tgfbr1fl/fl intestine. Error bars represent mean± S.E.M., n= 6 biological replicates. (f) qRT-PCR analysis of the stem cell markers Lgr5 and (g)
Olfm4 on CDS generated from Vil Apcfl/fl and Vil Apcfl/flTgfbr1fl/fl small intestine. Data are shown as ratios to the internal Gapdh control with error bars representing mean±
S.E.M., *P= 0.04 by Mann–Whitney test, one-tailed, n= 3 biological replicates
TGFβ blocks dedifferentiation
P Cammareri et al
1686
Cell Death and Differentiation
restricted to the VilCreERApcfl/+KrasG12D/+Tgfbr1fl/fl mice as
tumourigenesiswas also delayed inVilCreERApcfl/+KrasG12D/+
mice treated with AZD-6244.
To treat the VilCreERApcfl/+KrasG12D/+ mice for a similar
timeframe as the VilCreERApcfl/+KrasG12D/+Tgfbr1fl/fl mice, we
started the treatment of the VilCreERApcfl/+KrasG12D/+ mice
Figure 4 Loss of Tgfbr1 cooperates with WNTand KRAS activation to accelerate intestinal tumourigenesis. (a) Haematoxylin and eosin (H&E) and (b) bromodeoxyuridine
(BrdU) IHC on VilCreERApcfl/flKrasG12D/+ (Vil Apcfl/flKrasG12D/+) and VilCreERApcfl/flKrasG12D/+Tgfbr1fl/fl (Vil Apcfl/flKrasG12D/+Tgfbr1fl/fl) small intestine 3 days post induction with
tamoxifen. Black bars highlight the difference in the crypt length. Black arrows indicate the presence of proliferating cells along the villus in the VilCreERApcfl/flKrasG12D/+Tgfbr1fl/fl
genotype. Scale bars, 100 μm. (c) Quantification of the total BrdU+ cells per half crypt of the Vil Apcfl/flKrasG12D/+ and Vil Apcfl/flKrasG12D/+Tgfbr1fl/fl small intestine. Error bars
represent mean± S.E.M., *P= 0.04 by Mann–Whitney test, one-tailed, n= 3 biological replicates. (d) Kaplan–Meier survival curve of VilCreERApcfl/+KrasG12D/+ (n= 12) and
VilCreERApcfl/+KrasG12D/+Tgfbr1fl/fl (n= 15) mice, ****Po0.0001 by log-rank (Mantel–Cox) test. (e) H&E of top-down tumours in VilCreERApcfl/+KrasG12D/+Tgfbr1fl/fl (Vil Apcfl/+
KrasG12D/+ Tgfbr1fl/fl) mice. Scale bars, 100 μm. (f) Quantification of total tumour number per small intestine and colon developed from crypt (bottom-up) or villus (top-down) in
VilCreERApcfl/+KrasG12D/+ (Apc Kras) and VilCreERApcfl/+KrasG12D/+Tgfbr1fl/fl (Apc Kras Tgfbr1) mice. Error bars represent mean±S.E.M., *P= 0.023 by Mann–Whitney test,
one-tailed
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with Selumetinib 21 days post induction. Again, we were able
to delay significantly tumourigenesis (Supplementary
Figure 6a). Therefore, independent of the time of treatment
(initiation or tumour outgrowth), Selumetinib could delay but
not suppress tumourigenesis.
To assess if the reason for this is that Selumetinib affected
the compartment from which tumours arose, we quantified
top-down versus bottom-up lesions within the small intestine
and colon of both genotypes (Figures 6d and e and
Supplementary Figures 6b and c). MEK1/2 inhibition sup-
pressed the formation of top-down lesions, suggesting that in
both genotypes MAPK is important in the formation of this
lesion type. However, mice still develop lesions from the crypt
compartment, which led to the clinical signs. Thus, the MAPK
pathway, following oncogenic Kras activation, is in part
contributing to the increased plasticity of Apc-deficient cells.
Discussion
The TGFβ pathway is known to have both tumour-suppressing
and -promoting effects in cancer. This makes it complex when
trying to predict the outcome of therapies targeting the TGFβ
pathway. Here, we show a tumour-suppressive role of TGFβ
through its ability to limit tumour growth and dedifferentiation in
the early stages of CRC. Recent studies have highlighted that
plasticity of cells within the intestine act as stem cells and as
potential tumour-initiating cells. Ours and other studies have
highlighted that oncogenic Kras and inflammation can both
drive plasticity in part via the NF-κB pathway.6,8 We were able
to show that reducing NF-κB directly or indirectly viaRac1 loss
could further limit transformation and reduce stem cell
capacity.6,30 An excellent study using a carbonic anhydrase
Cre recombinase to target colonic enterocytes showed that
Apc loss and Kras activation, but not Apc loss alone, can drive
tumour growth in differentiated cells and generate ‘top-down’
tumours.31 Apart from these studies, very little is known about
the pathways that confer plasticity in adult intestinal epithe-
lium. Here, we show that loss of the TGFβ signalling pathway
induces the formation of more aggressive tumours, which are
mainly responsible for the significant reduction of the overall
survival. Interestingly, Tgfbr1 loss also increases the ability of
cells to dedifferentiate facilitating an increased number of top-
down lesions.
It is important to note that, at least in our systems, Kras
mutation is still necessary for dedifferentiation. Loss of TGFβ
signalling alone following Apc loss was not sufficient to drive
dedifferentiation. Moreover, although Tgfbr1 loss increases
Figure 5 Transforming growth factor-β (TGFβ) signalling attenuates the capacity of villi to dedifferentiate in vitro. (a) Morphology of villi freshly purified from VilCreERApcfl/
flKrasG12D/+ mice at day 1 (left panel) and day 4 (right panel) in culture. Black arrow indicates a spheroid inside the villus at day 4. (b) Quantification of VDS generated from Vil
Apcfl/flKrasG12D/+ and VilCreERApcfl/flKrasG12D/+Tgfbr1fl/fl (Vil Apcfl/flKrasG12D/+Tgfbr1fl/fl) intestine. Error bars represent mean± S.E.M., *P= 0.04 by Mann–Whitney test,
one-tailed, n= 3 biological replicates. (c) Quantification of VDS derived from VilCreERApcfl/flKrasG12D/+ villi treated with TGFβ1 (5 ng/ml) or Vehicle for 72 h. Plot represents mean
with standard deviation (s.d.), n= 3 biological replicates
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Figure 6 Loss of transforming growth factor-β (TGFβ) signalling causes sensitivity to MEK1/2 inhibition. (a) pERK IHC on VilCreERApcfl/flKrasG12D/+ (Vil Apcfl/flKrasG12D/+)
and VilCreERApcfl/flKrasG12D/+Tgfbr1fl/fl (Vil Apcfl/flKrasG12D/+Tgfbr1fl/fl) intestine. Scale bars, 100 μm. (b) Fluorescence lifetime changes for EKAREVnucl in VilCreERApcfl/fl
(Vil Apcfl/fl), Vil Apcfl/flKrasG12D/+ and Vil Apcfl/flKrasG12D/+Tgfbr1fl/f CDS±EGF (50 ng/ml). (Vil Apcfl/fl Δlifetime: − 0.08± 0.023, ****Po0.0001 by paired t-test, one-tailed; Vil
Apcfl/flKrasG12D/+: Δlifetime: − 0.12± 0.07, ****Po0.0001 by paired t-test, one-tailed; Vil Apcfl/flKrasG12D/+Tgfbr1fl/fl Δlifetime: − 0.14± 0.07, ****Po0.0001 by paired t-test,
one-tailed). Data for each condition are mean of differences± S.D. for ⩾ 10 cells, n= 1. VilCreERApcfl/flKrasG12D/++EGF versus VilCreERApcfl/flKrasG12D/+Tgfbr1fl/f +EGF,
**P= 0.003 by unpaired t-test, one-tailed. VilCreERApcfl/fl−EGF versus VilCreERApcfl/flKrasG12D/+−EGF, *P= 0.014 by unpaired t-test, one-tailed. VilCreERApcfl/flKrasG12D/+
−EGF versus VilCreERApcfl/flKrasG12D/+Tgfbr1fl/f –EGF, *P= 0.049 by unpaired t-test, one-tailed. (c) Kaplan–Meier survival curve of VilCreERApcfl/+KrasG12D/+ treated with
Selumetinib (Vil Apcfl/+KrasG12D/+, n= 7) or Vehicle (Vil Apcfl/+KrasG12D/+, n= 8), *P= 0.023 by log-rank (Mantel–Cox) test and VilCreERApcfl+KrasG12D/+Tgfbr1fl/fl mice treated
with Selumetinib (Vil Apcfl/+KrasG12D/+Tgfbr1fl/fl, n= 11) or Vehicle (Vil Apcfl/+KrasG12D/+Tgfbr1fl/fl, n= 6). ****Po0.0001 by log-rank (Mantel–Cox) test. Treatment started 1day
post induction with tamoxifen. (d) Quantification of top-down or bottom-up tumours in the small intestine (SI, left panel) and colon (right panel) of VilCreERApcfl/+KrasG12D/+
(Vil Apcfl/+KrasG12D/+) mice treated with Selumetinib or Vehicle. Error bars represent mean± S.E.M. (e) Quantification of top-down or bottom-up tumours in the SI (left panel) and
colon (right panel) of VilCreERApcfl/+KrasG12D/+Tgfbr1fl/fl (Vil Apcfl/+KrasG12D/+Tgfbr1fl/fl) mice treated with Selumetinib or Vehicle. Treatment started 1 day post induction with
tamoxifen. Error bars represent mean±S.E.M., Mann–Whitney test, two-tailed
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both the number of top-down lesions and presumably their
speed of formation, top-down lesions still arise in VilCreER-
Apcfl/+KrasG12D/+ mice that have functional TGFβ signalling.
We believe this might reflect a hierarchy of dedifferentiation
capacity. Thus, dependent on the precise location where the
lesions arise, they may be exposed to different levels of TGFβ
signals and this may be sufficient to block tumourigenesis from
some cells, while others (potentially exposed to lower levels of
TGFβ signals) are able to form top-down tumours that once
formed can grow regardless of these signals. It is interesting to
note that despite high levels of p21 in many lesions that arise
following Apc loss, deletion of p21 does not modify Apc
loss-induced tumourigenesis.32
It is interesting to note that other studies have suggested
that activation of TGFβ signalling might induce a stem cell
phenotype18 and an EMT programme.33–35 However, our
studies here indicate that exogenous TGFβ reduces organoid-
forming capacity in vitro in agreement with Alitalo laboratory’s
work, where exogenous TGFβ killed Apc-deficient crypts and
reduced ISC markers in vitro.36
Previously, it has been shown that TGFβ can positively
regulateMAPK signalling.37,38 In contrast, other studies fit with
our model where the TGFβ pathway can antagonize MAPK
signalling. TGFβ can regulate the expression of MKP2, which
in turn attenuates ERK.28 Moreover, oncogenic KrasG12D
along with TGFβ pathway inactivation has been associated
with increased expression of epiregulin and ERBB1.27
Recently, it has been reported that Tgfbr2 loss increases
Ras/MAPK/ERK activation in primary keratinocytes leading to
squamous cell carcinoma formation.39 Although our data
support the model that TGFβ signalling restrains pERK levels,
the mechanism by which this is achieved requires further
investigation.
The functional requirement for upregulated MAPK pathway
following Tgfbr1 loss was highlighted by MEK inhibition, which
markedly reduced the number of tumours arising with top-
down morphology. However, it is important to note that both
VilCreERApcfl/+KrasG12D/+ and VilCreERApcfl/+KrasG12D/+
Tgfbr1fl/fl mice still developed tumours (adenomas in the case
of VilCreERApcfl/+KrasG12D/+ mice and both adenoma/adeno-
carcinoma in VilCreERApcfl/+KrasG12D/+Tgfbr1fl/fl mice) that
have a bottom-upmorphology presumably originating from the
stem cell zone. This is an important finding showing that even
in a simplemousemodel system, where onlyApc andKras are
mutated, Kras mutant tumours originating from the stem cell
zone are resistant to MEK inhibition. These data are
consistent with the lack of efficacy of MEK inhibitors as a
single agent in advanced CRC carrying KRAS mutation
Figure 7 Schematic model of intestinal tumourigenesis. (a) Aberrant activation of WNTand KRAS signalling drives intestinal tumour formation both from crypts (bottom-up
model) and villi (top-down model). (b) High levels of transforming growth factor-β (TGFβ) signalling are present in the top-down model and this restrains tumourigenesis. (c) Loss
of Tgfbr1 promotes intestinal tumourigenesis. (d) Top-down tumours lacking of Tgfbr1 are sensitive to MEK1/2 inhibition
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(in both preclinical and clinical situations) as we would predict
that inhibition of MEK would only work at a much earlier stage
of tumourigenesis (e.g. during dedifferentiation).
In summary, we have defined that TGFβ signalling limits
dedifferentiation and tumourigenesis in cells carrying bothApc
and Kras mutations (model in Figure 7). This is in part due to
the gradients of TGFβ signalling in the intestine. Higher levels
of TGFβ in the stroma further up the crypt–villus axis means
that tumour-initiating cells in these regions are exposed to
tumour-suppressive signals. Importantly, when tumours grow
out from dedifferentiated cells, they seemed indistinguishable
from tumours arising from the crypt. This suggests that once
tumours have escaped the initial tumour-suppressive
mechanism, the cell of origin does not affect the ongoing
progression. Hence, mutational spectra might be a better way
of predicting the initial cells of origin rather than
transcriptomic data.
Materials and Methods
Mouse experiments. All experiments were performed in accordance with UK
Home Office regulations (licence 70/8646), which undergoes local ethical review at
the Glasgow University (Glasgow, UK). VillinCreER experiments were performed on
C57BL/6J mice and on mixed background (C57BL/6J/S129). A mix of males and
females were used. Mice were induced at >20 g and between 6 and 12 weeks of
age. The alleles used for this study were as follows: VilCreER-T2,40 Apc580S,41
KrasG12D,42 Tgfbr1fl,43 Smad4fl,44 CtnnbloxEx3/+45 and Xbp1s-CreER-T2.6 Recombi-
nation in the tumour model was induced using a single intraperitoneal injection of
80 mg/kg tamoxifen. Mice were aged until they showed clinical signs (anaemia,
hunching and/or weight loss).
Recombination in the short-term model was induced using a single intraperitoneal
injection of 80 mg/kg tamoxifen for 2 consecutive days. If KrasG12D allele was present,
recombination was induced using a single intraperitoneal injection of 80 mg/kg
tamoxifen. VilCreERCtnnbloxEx3/+KrasG12D/+ and Xbp1sCreERCtnnbloxEx3/+
KrasG12D/+ animals were induced with 1 mg tamoxifen for 5 consecutive days and
sampled at day 7 (for VilCreER) and day 21 (for Xbp1sCreER). For the villi purification,
mice were induced with intraperitoneal injection of 80 mg/kg tamoxifen for 2
consecutive days and sampled at day 1 post induction. The cultured villi treated with
TGFβ1 were isolated from mice that had been induced with a single intraperitoneal
dose of 80 mg/kg tamoxifen.
In accordance with the 3Rs, the smallest sample size was chosen that could give a
significant difference. Given the robust phenotype of the Apcfl/fl, and our prediction of
the role of TGFβ signalling, the minimum sample size assuming no overlap in control
versus experimental is three animals. No randomization was used and the
experimenter was blinded to drugs and genotypes.
In vivo treatment. Selumetinib (AZD6244, ARRY-142886; AstraZeneca,
Cambridge, UK) was administered in a concentration of 25 mg/kg two times daily
by gavage in a vehicle of 0.5% hydroxymethylpropylcellulose and 0.1% Tween-80.
For proliferation analysis, mice were injected intraperitoneally with 250 μl of BrdU
(Amersham Biosciences/GE Heathcare, Buckinghamshire, UK) 2 h before being
sampled.
Crypt/villus purification, propagation and treatment. Small intes-
tines were washed with PBS and opened longitudinally. Villi were removed with a
glass coverslip, washed in PBS and centrifuged at 60 × g for 3 min to separate villi
from single cells. A total of 50–70 villi, mixed with 20 μl of Matrigel (BD Bioscience/
Corning, Bedford, MA, USA), were plated in 24-well plates in Advanced DMEM/F12
supplemented with penicillin–streptomycin, 10 mM HEPES, 2 mM glutamine, N2,
B27 (all from Gibco, Life Technologies, Paisley, UK), and EGF (50 ng/ml) and
Noggin (100 ng/ml, both from Peprotech, London, UK). Crypts were isolated as
described previously.
46
Crypts mixed with 20 μl of Matrigel were plated in 24-well
plates and cultured in the medium described above.
Recombinant TGFβ1 (Peprotech) was used at a final concentration of 5 ng/ml.
Clonogenic assay. Organoid cultures were dissociated into single cells using
TrypLE Express (Gibco, Life Technologies) for 30–45 min at 37 °C and 5000 cells
were cultured in a 24-well plate in 20 μl of Matrigel (BD Bioscience). The clonogenic
potential was quantified after 72 h by microscope.
Transplantation. For transplantation experiments, 50 spheroids were
suspended in 100 μl Matrigel (BD Bioscience) and injected subcutaneously into
the flank of 6–8-week-old female athymic (CD-1) mice.
Immunohistochemistry. IHC was performed on formalin-fixed intestinal
sections. Standard IHC techniques were used throughout this study. Primary
antibodies used for immunohistochemistry were as follows: pSMAD3 (1:50; 52903;
Abcam, Cambridge, UK), BrdU (1:200; 347580; BD Biosciences), p21 (1/4; CNIO
Madrid, Spain), pERK (1:100; 9101; Cell SignalingTechnology, Leiden, The
Netherland) and CD44v6 (1:50; BMS145; Invitrogen/Thermo Fisher Scientific,
Vienna, Austria). For each antibody, staining was performed on at least three mice
of each genotype. Representative images are shown for each staining. BrdU scoring
was performed in a blinded manner. The number of positive cells per half crypt was
scored. For each analysis, at least 30 crypts were scored from at least three mice
for each genotype. Representative images were selected for each scoring.
RNAscope. In situ hybridization detection for Tgfb1, Tgfbr1, Smad7, Lgr5 and
Olfm4 mRNA was performed using RNAscope 2.5 LS (Brown) Detection Kit
(Advanced Cell Diagnostics, Hayward, CA, USA) on a Bond Rx autostainer (Leica,
Milton Keynes, UK) strictly according to the manufacturer's instructions.
Image analysis. For RNAscope and IHC analysis, intestinal slides were
scanned on an SCN400F slide scanner (Leica, Milton Keynes, UK). The files were
exported and analysed in Halo v2.0 Image Analysis Software (Indica Labs,
Corrales, NM, USA). For pSMAD3 quantification, areas were manually defined
around the more distinctly altered villus areas and the adjacent normal epithelium at
day 3 post induction. For Lgr5 and Olfm4 quantification, areas were manually
defined around the entire crypt and the more distinctly altered villus areas at day 3
post induction.
RNA purification. RNA was isolated using a Qiagen RNeasy Mini Kit (Qiagen,
Manchester, UK) according to the manufacturer’s instructions. DNA-Free Kit
(Ambion/Thermo Fisher Scientific, Warrington, UK) was used to remove genomic
DNA contamination, according to the manufacturer’s instructions.
Microarray analysis. One microgram of total RNA isolated from intestinal
tissue was reverse transcribed to cDNA and hybridized to Affymetrix Mouse
Genome 430 2.0 Microarrays (Santa Clara, CA, USA). The data were preprocessed
using affy package47 in R language, version 2.15.0. Background correction, quantile
normalization and probe summarization were performed using the Robust
Multiarray Analysis algorithm. Normalized data were analysed using the Limma
package.48 Gene Ontology annotation was added using the GO.db package.
Affymetrix Mose Gene ST 1.0 Chip (Santa Clara, CA, USA) has been used to
analyse the VilCreERCtnnbloxEx3/+KrasG12D/+ and Xbp1sCreERCtnnbloxEx3/
+KrasG12D/+ genotype. Data have been deposited in NCBI GEO (https://www.
ncbi.nlm.nih.gov/geo/) and are accessible through GEO series accession numbers:
GSE99077, GSE99100, GSE99408.
Quantitative PCR (qRT-PCR). One microgram of RNA was reverse
transcribed to cDNA using a DyNAmo SYBR Green 2-Step qPCR Kit (Finnzymes,
Espoo, Finland) in a reaction volume of 20 μl. The cycling conditions were as
follows: 95 °C for 15 min, followed by 40 cycles of three steps consisting of
denaturation at 94 °C for 15 s, primer annealing at the optimal temperature for 30 s
and primer extension at 72 °C for 30 s. A melting-curve analysis was performed to
demonstrate the specificity of each amplicon and to identify the formation of primer
dimers. β-Actin and Gapdh primers were used to normalize for differences in
RNA input.
Transfection. For transfection experiments, intestinal spheroids were seeded in
96-well plates and transfected with EKAREV construct and Super PiggyBac
Transposase expression vector (System Biosciences, Palo Alto, CA, USA) by using
Magnetofectamine (OZ Biosciences, Marseille, France) according to the
manufacturer's instructions. Subsequently, cells were incubated for 48 h at 37 °C
and 5% CO2. After 48 h, organoids were selected using blasticidin.
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FLIM analysis. Fluorescence lifetime microscopy (FLIM) measurements were
conducted on a spinning disk system, as described previously.49 Briefly, a Nikon
Eclipse TE 2000-U microscope (Surrey, UK) with a Lambert Instruments LIFA
attachment was used with a Yokogawa CSU 22 confocal scanner unit and a × 60
1.49 NA oil objective. FLIM-FRET for the msECFP donor was measured by
frequency domain, with a 445 nm laser modulated at 40 mHz (100 mW, Deepstar;
Omicron, Rodgau-Dudenhofen, Germany) was used together with a CFP filterblock
(470/40) to detect CFP emission. Fluorescein (10 μM in 0.1 M Tris-Cl, pH410) was
used as a reference standard with a known lifetime of 4.0 ns. The donor lifetime
(msECFP29), τ, was analysed using the FLIM Software (version 1.2.12; Lambert
Instruments, Groningen, Netherlands) drawing ROIs around the cell nuclei and
recording the phase lifetime. Graph represents the lifetime variation (ns) before and
after (45 min)±EGF (50 ng/ml) administration. In both cases, the mean of
differences and standard deviation is calculated and represented P-values were
calculated using Student’s t-test.
Statistical analysis. Statistical analysis was performed with Minitab 17
Statistical Software (State College, PA, USA) or GraphPad Prism V6 Software (La
Jolla, CA, USA) using one- or two-tailed Mann–Whitney tests and paired or
unpaired Student’s t-tests (where appropriate).
Data availability. The authors declare that all relevant data supporting the
findings of this study are available within the article and its Supplementary
Information files. Additional information can be obtained from the corresponding
author (OJS).
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